View Post

Ancestry-specific genetic risk examined for triple-negative breast cancer

In In The News by Barbara Jacoby

From: medicalxpress.com Women of African ancestry more often have a personal history of triple-negative breast cancer (TNBC), but the magnitudes of gene-specific risks for TNBC are similar across different racial/ethnic groups, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago. Michael J. Hall, M.D., from …

View Post

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

In In The News by Barbara Jacoby

By: Joyce A. O’Shaughnessy, MD, Sara A. Hurvitz, MD From: onclive.com Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer. Transcript: Joyce A. O’Shaughnessy, MD: Let’s go on to the third data set, which is the KEYNOTE-522. We’re finally getting a big advance for patients with high-risk TNBC [triple-negative breast cancer] in …

View Post

European Commission Approves Keytruda in Early-Stage Triple-Negative Breast Cancer

In In The News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Merck said Tuesday that the European Commission approved its anti-PD-1 therapy Keytruda (pembrolizumab) as a treatment for earlier stages of triple-negative breast cancer. Keytruda is already available in Europe for locally recurrent, unresectable or metastatic TNBC. The new approval will allow TNBC patients with locally advanced or early-stage disease to use Keytruda and chemo before …

View Post

UF Scripps researcher’s drug-discovery method shows promise against aggressive breast cancer

In In The News by Barbara Jacoby

From: ufhealth.org UF Scripps Biomedical Research scientist Matthew Disney, Ph.D. has found yet another groundbreaking approach to a problem that has long vexed scientists: How to cure diseases by targeting key RNA. Until now, RNA has been an elusive target for drug discovery. Discoveries made by Disney and his collaborators have rewritten that dogma. The group’s recent discoveries have important, …

View Post

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center

In In The News by Barbara Jacoby

New clinical trial is focused on novel therapy for triple negative breast cancer When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused …

View Post

Cardamonin shows promise for treating aggressive breast cancer

In In The News by Barbara Jacoby

By Experimental Biology From: medicalxpress.com Cardamonin—a natural compound found in the spice cardamom and other plants—could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells. The findings also show that the compound targets a gene that helps cancer cells elude the immune system. About 10-15% of breast cancers are triple-negative, which means they …

View Post

Health supplement MitoQ world’s first to stop breast cancer recurrence and spread?

In In The News by Barbara Jacoby

By: Study Finds From: studyfinds.org In a world-first, scientists have found a drug that can halt the recurrence and spread of breast cancer. The treatment, called the MitoQ molecule, stopped cancer’s spread in 80 percent of cases and recurrence in 75 percent of patients. Researchers in Belgium are calling the discovery a “giant step” in beating the disease. After originally …

View Post

Research findings may explain marked racial disparity in deaths from triple negative breast cancer

In In The News by Barbara Jacoby

Source: Johns Hopkins Medicine From: news-medical.net Different activity in two molecular networks could help explain why triple negative breast cancers tend to be more aggressive in African American (AA) women compared with white American (WA) women, a new study led by Johns Hopkins Kimmel Cancer Center researchers suggests. The findings, published online on Dec. 20 in eLife, may explain the …

View Post

Scientists Identify Gene Driving Breast Cancer Metastasis

In In The News by Barbara Jacoby

From: clinicaloncology.com Researchers have pinpointed the gene that’s responsible for metastatic triple-negative breast cancer, according to a recently published study. Reporting in Science Translational Medicine (2022 Feb 2. doi:10.1126/scitranslmed.abf5473), the researchers detailed the role of the CECR2 gene in breast cancer metastasis. “We are constantly searching for new effective therapeutic strategies to help patients with this potentially deadly disease,” senior …

View Post

Phoenix Molecular Designs Successfully Completes Patient Enrollment in Phase 1/1b Clinical Trial of PMD-026

In In The News by Barbara Jacoby

Source: Phoenix Molecular Design From: PR Newwire Phoenix Molecular Designs (PhoenixMD), a clinical stage biopharmaceutical company dedicated to developing precise cancer therapeutics, today announced the completion of patient enrollment and dosing of PMD-026 in their Phase 1b monotherapy clinical trial. The successful completion of patient enrollment in this Phase 1/1b trial is an important step forward for PhoenixMD as they advance …